MPC
44
3
INTU
60
-3
AKAM
56
-2
CHD
53
-3
PPL
60
-7
ECL
69
-3
EIX
69
-5
GT
46
3
CCI
36
-5
EQT
44
2
NTRS
47
-2
HRL
38
2
NTAP
58
2
D
55
-6
CRM
50
-5
NEE
52
-2
UNP
48
-2
TJX
50
2
AVB
65
-2
PG
51
-2
MPC
44
3
INTU
60
-3
AKAM
56
-2
CHD
53
-3
PPL
60
-7
ECL
69
-3
EIX
69
-5
GT
46
3
CCI
36
-5
EQT
44
2
NTRS
47
-2
HRL
38
2
NTAP
58
2
D
55
-6
CRM
50
-5
NEE
52
-2
UNP
48
-2
TJX
50
2
AVB
65
-2
PG
51
-2
Financhill
Back

Takeda Pharmaceutical 10K Form

Sell
33

TAK
Takeda Pharmaceutical

Last Price:
14.93
Seasonality Move:
-4.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TAK News And Ratings

See the #1 stock for the next 7 days that we like better than TAK

TAK Financial Statistics

Sales & Book Value

Annual Sales: $29.55B
Cash Flow: $208.52M
Price / Cash Flow: 15.03
Annual Sales: $15.44
Price / Book: 0.97

Profitability

EPS (TTM): 0.30580
Net Income (TTM): $974.15M
Gross Margin: $19.66B
Return on Equity: 2.03%
Return on Assets: 0.97%

Takeda Pharmaceutical Earnings Forecast

Key Takeda Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 25 years for TAK is 66.54%.
  • The Selling, General & Administrative Expenses for TAK have been equal to 24.72% of Gross Profit Margin.
  • The Research & Development expenses have been 17.12% of Revenue.
  • The Interest Expense is 82.97% of Operating Income.
  • The Net Earning history of TAK is 3.38% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 15 years.

Takeda Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TAK
CUSIP: 874060
Website: takeda.com

Debt

Debt-to-Equity Ratio: 0.7
Current Ratio: 1.26
Quick Ratio: 0.66

Price-to-Earnings

Trailing P/E Ratio: 46.92
Forward P/E Ratio: 0

TAK Technical Analysis vs Fundamental Analysis

Sell
33
Takeda Pharmaceutical (TAK) is a Sell

Is Takeda Pharmaceutical a Buy or a Sell?